JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Billman, G. E.
Right arrow Articles by Schölkens, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Billman, G. E.
Right arrow Articles by Schölkens, B. A.

Vol. 286, Issue 3, 1465-1473, September 1998

HMR 1883, a Novel Cardioselective Inhibitor of the ATP-Sensitive Potassium Channel. Part II: Effects on Susceptibility to Ventricular Fibrillation Induced by Myocardial Ischemia in Conscious Dogs

George E. Billman, Heinrich C. Englert and Bernward A. Schölkens

Department of Physiology, The Ohio State University, Columbus, Ohio, and Hoechst-Marion-Roussel, DG Cardiovascular, Frankfurt Germany

The activation of the ATP-sensitive potassium channel (KATP) during myocardial ischemia leads to potassium efflux, reductions in action potential duration and the formation of ventricular fibrillation (VF). Drugs that inactivate KATP should prevent these changes and thereby prevent VF. However, most KATP antagonists also alter pancreatic channels, which promote insulin release and hypoglycemia. Recently, a cardioselective KATP antagonist, HMR 1883, has been developed that may offer cardioprotection without the untoward side effects of existing compounds. Therefore, VF was induced in 13 mongrel dogs with healed myocardial infarctions by a 2-min coronary artery occlusion during the last minute of a submaximal exercise test. On subsequent days, the exercise-plus-ischemia test was repeated after pretreatment with HMR 1883 (3.0 mg/kg i.v., n = 13) or glibenclamide (1.0 mg/kg i.v., n = 7). HMR 1883 (P < .001) and glibenclamide (P < .01) prevented VF in 11 of 13 and 6 of 7 animals, respectively. Glibenclamide, but not HMR 1883, elicited increases in plasma insulin and reductions in blood glucose. Glibenclamide also reduced (P < .01) both mean coronary blood flow and left ventricular dP/dt maximum as well as the reactive hyperemia induced by 15-sec coronary occlusions (-30.3 ± 11%), whereas HMR 1883 did not alter this increase in coronary flow (-3.0 ± 4.7%). Finally, myocardial ischemia (n = 10) significantly (P < .01) reduced refractory period (control, 121 ± 2 msec; occlusion, 115 ± 2 msec), which was prevented by either glibenclamide or HMR 1883. Thus, the cardioselective KATP antagonist HMR 1883 can prevent ischemically induced reductions in refractory period and VF without major hemodynamic effects or alterations in blood glucose levels. These data further suggest that the activation of KATPs may play a particularly important role in both the reductions in refractory period and lethal arrhythmia formation associated with myocardial ischemia.

0022-3565/98/2863-1465$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 EuropaceHome page
I. Savelieva and J. Camm
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches
Europace, June 1, 2008; 10(6): 647 - 665.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Sato, A. D. T. Costa, T. Saito, T. Ogura, H. Ishida, K. D. Garlid, and H. Nakaya
Bepridil, an Antiarrhythmic Drug, Opens Mitochondrial KATP Channels, Blocks Sarcolemmal KATP Channels, and Confers Cardioprotection
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 182 - 188.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
B. O'Rourke, S. Cortassa, and M. A. Aon
Mitochondrial Ion Channels: Gatekeepers of Life and Death
Physiology, October 1, 2005; 20(5): 303 - 315.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. Jovanovic and A. Jovanovic
High Glucose Regulates the Activity of Cardiac Sarcolemmal ATP-Sensitive K+ Channels via 1,3-Bisphosphoglycerate: A Novel Link Between Cardiac Membrane Excitability and Glucose Metabolism
Diabetes, February 1, 2005; 54(2): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. J. Canyon and G. P. Dobson
Protection against ventricular arrhythmias and cardiac death using adenosine and lidocaine during regional ischemia in the in vivo rat
Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1286 - H1295.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. S. Fischbach, A. White, T. D. Barrett, and B. R. Lucchesi
Risk of Ventricular Proarrhythmia with Selective Opening of the Myocardial Sarcolemmal versus Mitochondrial ATP-Gated Potassium Channel
J. Pharmacol. Exp. Ther., May 1, 2004; 309(2): 554 - 559.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. E. Billman, M. S. Houle, H. C. Englert, and H. Gogelein

J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 182 - 192.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
B. O'Rourke
Evidence for Mitochondrial K+ Channels and Their Role in Cardioprotection
Circ. Res., March 5, 2004; 94(4): 420 - 432.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Sato, T. Takizawa, T. Saito, S. Kobayashi, Y. Hara, and H. Nakaya
Amiodarone Inhibits Sarcolemmal but Not Mitochondrial KATP Channels in Guinea Pig Ventricular Cells
J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 955 - 960.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
U. Russ, U. Lange, C. Loffler-Walz, A. Hambrock, and U. Quast
Interaction of the Sulfonylthiourea HMR 1833 with Sulfonylurea Receptors and Recombinant ATP-Sensitive K+ Channels: Comparison with Glibenclamide
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1049 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. F. del Valle, E. C. Lascano, J. A. Negroni, and A. J. Crottogini
Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep
Cardiovasc Res, June 1, 2001; 50(3): 474 - 485.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Toyoda, I. Friehs, R. A. Parker, S. Levitsky, and J. D. McCully
Differential role of sarcolemmal and mitochondrial KATP channels in adenosine-enhanced ischemic preconditioning
Am J Physiol Heart Circ Physiol, December 1, 2000; 279(6): H2694 - H2703.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
R. A. Li, M. Leppo, T. Miki, S. Seino, and E. Marban
Molecular Basis of Electrocardiographic ST-Segment Elevation
Circ. Res., November 10, 2000; 87(10): 837 - 839.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
B. O'Rourke
Myocardial KATP Channels in Preconditioning
Circ. Res., November 10, 2000; 87(10): 845 - 855.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. M. Fryer, A. K. Hsu, H. Nagase, and G. J. Gross
Opioid-Induced Cardioprotection against Myocardial Infarction and Arrhythmias: Mitochondrial versus Sarcolemmal ATP-Sensitive Potassium Channels
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 451 - 457.
[Abstract] [Full Text]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
R. M. Fryer, J. T. Eells, A. K. Hsu, M. M. Henry, and G. J. Gross
Ischemic preconditioning in rats: role of mitochondrial KATP channel in preservation of mitochondrial function
Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H305 - H312.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. J. Lynch Jr, M. S. Houle, G. L. Stump, A. A. Wallace, D. B. Gilberto, H. Jahansouz, G. R. Smith, A. J. Tebben, N. J. Liverton, H. G. Selnick, et al.
Antiarrhythmic Efficacy of Selective Blockade of the Cardiac Slowly Activating Delayed Rectifier Current, IKs, in Canine Models of Malignant Ischemic Ventricular Arrhythmia
Circulation, November 2, 1999; 100(18): 1917 - 1922.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. J. Wirth, B. Rosenstein, J. Uhde, H. C. Englert, A. E. Busch, and B. A. Schölkens
ATP-Sensitive Potassium Channel Blocker HMR 1883 Reduces Mortality and Ischemia-Associated Electrocardiographic Changes in Pigs with Coronary Occlusion
J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 474 - 481.
[Abstract] [Full Text]

Home page
 Circ. Res.Home page
G. J. Gross and R. M. Fryer
Sarcolemmal Versus Mitochondrial ATP-Sensitive K+ Channels and Myocardial Preconditioning
Circ. Res., May 14, 1999; 84(9): 973 - 979.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Gögelein, J. Hartung, H. C. Englert, and B. A. Schölkens
HMR 1883, a Novel Cardioselective Inhibitor of the ATP-Sensitive Potassium Channel. Part I: Effects on Cardiomyocytes, Coronary Flow and Pancreatic beta -Cells
J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1453 - 1464.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.